Loading...
Market
In which quarter of 2024 will Kailera Therapeutics release its first obesity treatment to the market?
3
Kailera Therapeutics•Hercules CM NewCo•Ron Renaud•Atlas Venture•Bain Capital Life Sciences•RTW Investments
Resolution / Starting Odds
Q1 2024 • 25%
Q2 2024 • 25%
Q3 2024 • 25%
Q4 2024 • 25%
Official press releases from Kailera Therapeutics and market reports
Story
Kailera Therapeutics Raises $400M in Series A Financing for Obesity Treatments, Ron Renaud as CEO
Oct 1, 2024, 11:30 AM
Kailera Therapeutics, an obesity treatment developer, has raised $400 million in a Series A financing round. The startup, previously known as 'Hercules CM NewCo,' is led by CEO Ron Renaud, who has a track record of successful acquisitions. The funding round, announced on Tuesday, was backed by Atlas Venture, Bain Capital Life Sciences, and RTW Investments. This significant investment underscores the competitive nature of the obesity drug market, with Kailera Therapeutics aiming to advance its portfolio of next-generation therapies for obesity and related conditions. The company is already striking a deal for commercial manufacturing.
View original story
Similar markets
Pfizer • 25%
Roche • 25%
GlaxoSmithKline • 25%
Other • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Pfizer • 25%
Other • 25%
Exceeds expectations • 25%
Meets expectations • 25%
Falls short of expectations • 25%
Trial cancelled • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Approve continuation • 25%
Request modifications • 25%
Suspend trial • 25%
No action taken • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
United States • 25%
European Union • 25%
China • 25%
None of the above • 25%
